A Novel Grading System Based on Tumor Budding and Cell Nest Size Is a Strong Predictor of Patient Outcome in Esophageal Squamous Cell Carcinoma
Moritz Jesinghaus(Philipps University of Marburg), Wilko Weichert(Deutsches Konsortium für Translationale Krebsforschung), Melanie Boxberg(Starnberg Hospital), Katja Ott(Technical University of Munich), Arndt Hartmann(Universitätsklinikum Erlangen), Björn Konukiewitz(University Hospital Schleswig-Holstein), Anna Melissa Schlitter(German Cancer Research Center), Julia Slotta‐Huspenina(Technical University of Munich), İhsan Ekin Demir(TUM Klinikum), Katja Specht(Technical University of Munich), Arne Warth(Heidelberg University), Markus Feith(TUM Klinikum), Katja Steiger(Technical University of Munich), Kathrin Wieczorek(Technische Universität Dresden), Thomas Schmidt(Heidelberg University)
Cited by 63
Related Papers
Mass-spectrometry-based draft of the human proteome
|Nature|2014|1.9k
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
|Nature Communications|2016|727
Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954
|Journal of Clinical Oncology|2010|714
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464